Status:
COMPLETED
Neurodevelopment at 5.5 Years of Age in Children Who Received Infant Formula With Enriched Protein Fractions
Lead Sponsor:
Mead Johnson Nutrition
Conditions:
Cognitive Ability, General
Eligibility:
All Genders
64-68 years
Brief Summary
This is a follow-up study of a multi-center, double-blind, randomized, controlled, parallel-designed, prospective trial and is intended to evaluate neurodevelopment at 5.5 years of age and health outc...
Eligibility Criteria
Inclusion
- Participant who previously consumed study formula through one year of age in MJN Project 6027
- 5 years of age (i.e. when child turns 5 years and 6 months old ± 2 months) at Visit 1
- Signed informed consent obtained for child's participation in the study
Exclusion
- No exclusion criteria
Key Trial Info
Start Date :
June 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 27 2021
Estimated Enrollment :
116 Patients enrolled
Trial Details
Trial ID
NCT04442477
Start Date
June 15 2020
End Date
May 27 2021
Last Update
December 16 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fuyang Fifth People's Hospital
Anhui, China